The assessment of metabolic syndrome in UK patients with HIV using two different definitions: CREATE 2 study
Authors:
- 22 November 2010
- journal article
- research article
- Published by Informa Healthcare in Current Medical Research and Opinion
- Vol. 27 (1) , 63-69
Abstract
To determine the prevalence and clinical associations of the metabolic syndrome (M-IRS) in an HIV cohort. Data was collected prospectively on demographics, anthropometry, HIV disease, drug regimens and cardiometabolic risk factors using a two-centre cross-sectional cohort study design. M-IRS was diagnosed by National Cholesterol Education Program (NCEP) and International Diabetes Federation (IDF) criteria. The prevalence of M-IRS in 678 subjects was 14% by NCEP and 10% by IDF. One feature of the M-IRS was present in 68%, while 37% had two or more features. Increased waist circumference was found in 32% by NCEP or by IDF criteria, hypertriglyceridaemia in 32%, reduced HDL-C in 27%, 18% had raised systolic blood pressure and 13% had dysglycaemia. Protease inhibitor (PI) usage was similar in both M-IRS categories (43 vs. 38%; p = 0.38) but increased use of efavirenz was seen in M-IRS (47 vs. 36%; p = 0.07) and nevirapine in the non-M-IRS groups (10 vs. 20%; p = 0.05). Multiple drug therapies were associated with raised triglyceride levels while nevirapine therapy was associated with raised HDL-C and abacavir with dysglycaemia. The prevalence of M-IRS in this HIV cohort was similar to the general population and independent of current or previous highly active antiretroviral therapy (HAART) or its duration. Given the relationship between individual drugs and features of M-IRS its significance must be interpreted in the light of probable accrual bias in prescribing. Prospective studies are required to ascertain the cardiometabolic risk factors to include in a prognostically useful HIV disease-specific definition of M-IRS.Keywords
This publication has 39 references indexed in Scilit:
- Nevirapine Increases High-Density Lipoprotein Cholesterol Concentration by Stimulation of Apolipoprotein A-I ProductionArteriosclerosis, Thrombosis, and Vascular Biology, 2009
- The prevalence of metabolic syndrome in Danish patients with HIV infection: the effect of antiretroviral therapyHIV Medicine, 2009
- HIV lipodystrophy and its metabolic consequences: implications for clinical practiceCurrent Medical Research and Opinion, 2008
- Metabolic Syndrome in HIV-Infected Patients from an Urban, Midwestern US Outpatient PopulationClinical Infectious Diseases, 2007
- Diagnosis and Management of the Metabolic SyndromeCirculation, 2005
- Dyslipidaemia and cardiovascular risk in HIV infectionCurrent Medical Research and Opinion, 2005
- Metabolic syndrome: Definition, pathophysiology, and mechanismsAmerican Heart Journal, 2005
- Prevalence of the Metabolic Syndrome and Its Relation to All-Cause and Cardiovascular Mortality in Nondiabetic European Men and WomenArchives of internal medicine (1960), 2004
- Metabolic Abnormalities and Cardiovascular Disease Risk Factors in Adults with Human Immunodeficiency Virus Infection and LipodystrophyClinical Infectious Diseases, 2001
- Evidence for insulin resistance in black women from South AfricaInternational Journal of Obesity, 2000